Crossmark

T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany

Crossref DOI link: https://doi.org/10.1038/s41409-024-02505-x

Published Online: 2025-01-22

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ahmadi, P.

Alsdorf, W.

Leypoldt, L. https://orcid.org/0000-0002-9248-588X
Kosch, R.

Schaefers, C.

Gagelmann, N.

Ayuk, F. https://orcid.org/0000-0001-6297-1847
Kron, F.

Weisel, K. https://orcid.org/0000-0001-9422-6614
License Information

Text and Data Mining valid from 2025-01-22

Version of Record valid from 2025-01-22
More Information

Article History

Received: 6 October 2024

Revised: 12 December 2024

Accepted: 23 December 2024

First Online: 22 January 2025

Competing interests

: PA: no competing interests. WA: Travel expenses/congress support: Immatics, BioNTech, Janssen. Research funding (Instiution): Affimed, BioNTech. Advisory Role and Honoraria: Immatics, GSK, Astellas, AstraZeneca,Janssen. LL: Advisory Role and Honoraria: Adaptive, AbbVie, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi. Research Funding: AbbVie, GlaxoSmithKline. Travel Support: Oncopeptides, Sanofi. RK: travel grants by Amgen. CS: consultancy for Acus Health, Astra Zeneca, Janssen-Cilag, Menarini Stemline, Pfizer; honoraria from Abbvie, Astra Zeneca, Janssen-Cilag; other (travel expenses/congress support): Acus Health, Astra Zeneca, Bristol Myers Squibb, Menarini Stemline, oncopeptides, Sanofi. NG: Advisory Role and Honoraria: Bristol Myers Squibb/Celgene, Stemline, Pfizer, Kite/Gilead, Janssen-Cilag/J&J. FA: Honoraria: Medac, Takeda, Kite/Gilead, BMS/Celgene, Janssen, Miltenyi Biomedicine, Novartis, AbbVie, Mallinkrodt/Therakos. Research funding: Mallinckrodt/Therakos. FK: employed by VITIS GmbH and holds a professorship at FOM University of Applied Sciences for Economics and Management. KW: Research Grant: Abbvie, Amgen, BMS/Celgene, GSK, Janssen, Sanofi (to the Institution) Honoraria: Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, Beigene, BMS, Celgene, Janssen, GSK, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, Takeda Adisory Board: Abbvie, Amgen, Adaptive Biotech, Beigene, BMS, Celgene, Janssen, GSK, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Takeda.

Document is current

Any future updates will be listed below